In This Section

Program

Opening Keynote Lecture
Plenary Session 1: Molecular Pathogenesis of Hepatocellular Carcinoma
Plenary Session 2: Inflammation and Liver Cancer
Plenary Session 3: Risk Factors, Surveillance, and Molecular Detection
Plenary Session 4: Molecular Targeted Therapies in HCC
Plenary Session 5: Immunotherapies in HCC: Molecular Mechanisms and Combination Regimens
Plenary Session 6: Trial Design and Endpoints in HCC
Plenary Session 7: Molecular Pathogenesis and Drivers of Cholangiocarcinoma
Plenary Session 8: Molecular Targeted Therapies and Precision Oncology in iCCA
Plenary Session 9: Molecular Pathogenesis and Treatment of Hepatoblastoma
Closing Keynote Lecture

Thursday, May 5, 2022

Registration
3:30-7:30 p.m.
Welcome and Opening Remarks
6:30 p.m.-6:45 p.m.

Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, California

Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, New York

Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France


Opening Keynote Lecture
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
6:45 p.m.-7:30 p.m.

Introduction   
Josep M. Llovet

Molecular drivers in hepatocellular carcinoma: The story of what we know and what are we missing                                                                                      
Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France

Friday, May 6 2022

Plenary Session 1: Molecular Pathogenesis of Hepatocellular Carcinoma
Session Chair: Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France
8-10 a.m.

The good and the bad sides of tertiary lymphoid structures in liver cancer
Eli Pikarsky, The Hebrew University of Jerusalem, Jerusalem, Israel

Polyploidy, DNA damage response driver or gatekeeper of chronic liver diseases
Chantal Desdouets, Cordeliers Research Center at INSERM, Paris, France      

Short-talks from proffered papers & discussion

Break
10-10:30 a.m.
Plenary Session 2: Inflammation and Liver Cancer
10:30 a.m.-12:30 p.m.

                               
Metabolic control of HCC development  
Michael Karin, University of California at San Diego, La Jolla, California

Immune mechanisms driving carcinogenesis in NASH
Matthias Heikenwälder, German Cancer Research Center, Heidelberg, Germany   

Mechanisms of immune escape in hepatocellular carcinoma
Amaia Lujambio, Icahn School of Medicine at Mount Sinai, New York, New York

Short-talks from proffered papers

Poster Session A / Lunch
12:30-2:30 p.m.
Plenary Session 3: Risk Factors, Surveillance, and Molecular Detection
2:45-4:45 p.m.

Epidemiology and emerging risk factors in liver cancer                                               
Hashem B. El-Serag, Baylor College of Medicine, Houston, Texas

Surveillance for HCC in at-risk populations: Current perspectives and future directions  
 Amit Singal, UT Southwestern Medical Center, Dallas, Texas                          

Role of liquid biopsy in early detection and assessment of response in HCC
Augusto Villanueva, Icahn School of Medicine at Mount Sinai, New York, New York      

Molecularly-derived prognosis in HCC: truncal mutations vs acquired aberrations defining outcome
Jean-Charles Nault, INSERM, Paris, France 

Dinner on own / Evening off
5:30 p.m.-

Saturday, May 7, 2022

Plenary Session 4: Molecular Targeted Therapies in HCC
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
8-9:30 a.m.

Molecular targeted therapies for advanced HCC                                               
Josep M. Llovet

Prognostic and predictive biomarkers for cabozantinib in HCC
Lorenza Rimassa, Humanitas University, Rozzano, Italy

FDA perspective on accelerated and regular approvals in HCC and cholangiocarcinoma
Steven Lemery, U.S. Food and Drug Administration, Silver Spring, Maryland

Break
9:30-10 a.m.
Plenary Session 5: Immunotherapies in HCC: Molecular Mechanisms and Combination Regimens
Session Chair: Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA
10-11:30 a.m.

Immune checkpoint inhibitors and NAFLD                                                              
Tim F. Greten, National Cancer Institute, Bethesda, Maryland

Impact of single checkpoint inhibitors and biomarkers of response
Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, Los Angeles, California

Combination therapies including checkpoint inhibitors in HCC: the dawn of a new era  
Richard S. Finn

Poster Session B / Lunch
11:30 a.m.-1:30 p.m.
Plenary Session 6: Trial Design and Endpoints in HCC
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
1:30-3:30 p.m.

Trial Design and endpoint definition in intermediate stage HCC – a challenge  
Peter R. Galle, University Medical Center Mainz, Mainz, Germany

Lessons learnt from phase III trials in HCC: OS, PFS and ORR
Andrew X. Zhu, Massachusetts General Hospital, Boston, Massachusetts

Trial enrichment and proof of concept studies                                                
Augusto Villanueva, Icahn School of Medicine at Mount Sinai, New York

Assessing response and time-to-event end-points: RECIST and mRECIST
Riccardo Lencioni, University of Pisa, Pisa, Italy

Break
3:30-4 p.m.
Plenary Session 7: Molecular Pathogenesis and Drivers of Cholangiocarcinoma
4-6 p.m.

Molecular pathogenesis and cell of origin of intrahepatic cholangiocarcinoma (iCCA)
Sumera Ilyas, Mayo Clinic, Rochester, Minnesota

Molecular classes and landscape of drivers of iCCA and eCCA    
Daniela Sia, Icahn School of Medicine at Mount Sinai, New York, New York                                           

Dissecting molecular differences between iCCA and eCCA
Xin Wei Wang, National Cancer Institute, Bethesda, Maryland                                         

Short-talks from proffered papers

Dinner on own / Evening off
5:30 p.m.-

Sunday, May 8, 2022

Plenary Session 8: Molecular Targeted Therapies and Precision Oncology in iCCA
8-10 a.m.

Clinical trials and molecular therapies in iCCA
Juan Valle, University of Manchester, Manchester, England

IDH Inhibitors: Rationale, molecular mechanisms and benefit
Andrew X. Zhu, Massachusetts General Hospital, Boston, MA

FGFR2 fusion inhibitors: Clinical benefit and mechanisms of resistance
Mitesh Borad, Mayo Clinic, Scottsdale, Arizona

Trial Design in the era of precision oncology and combination therapies
John Bridgewater, University College London, London, England

Break
10-10:30 a.m.
Plenary Session 9: Molecular Pathogenesis and Treatment of Hepatoblastoma
10:30-11:30 a.m.

Advances in the pathogenesis and classification of pediatric hepatocellular neoplasms
Dolores H. Lopez-Terrada, Texas Children’s Hospital, Houston, Texas

Present and future of precision oncology in hepatoblastoma
Speaker to be announced

Closing Keynote Lecture
Session Chair: Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY
11:30 A.M.-12:30 P.M.

Introduction
Josep M. Llovet    

Present and future of pathogenesis and molecular treatment of iCCA
Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, New York, New York

Closing Remarks
12:30 p.m.

Richard S. Finn, Geffen School of Medicine at UCLA, Santa Monica, CA

Josep M. Llovet, Icahn School of Medicine at Mount Sinai, New York, NY

Jessica Zucman-Rossi, Cordeliers Research Center at INSERM, Paris, France